ASCO MEETING: Adaptive Control Reduces Side Effects Of High-Dose
Chemotherapy
[05/18/99; Doctor's Guide]
ATLANTA, GA -- May 18, 1999 -- Research conducted at City of Hope
Cancer Center in Los Angeles suggests that the most serious and
costly side effects of high-dose chemotherapy -- including long-term
hospitalisation and severe inflammation of the mouth -- can be
reduced by a new approach to adjusting dosage of Bristol-Myers
Squibb Co.'s chemotherapy agent Taxol (Paclitaxel).
This approach, termed adaptive control, adjusts dosage based
on actual blood levels of Taxol. The results of the research
were presented at the 1999 American Society of Clinical Oncology's
(ASCO) annual meeting by James Doroshow, MD, director of the
department of medical oncology and therapeutics research at City
of Hope.
The full article can be found at:
http://www.pslgroup.com/dg/fe526.htm
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
